ArticleBMC cancer2026
Identification and verification of an eight-gene prognostic signature for colorectal cancer based on tumor-associated macrophages.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTumor-associated macrophages (TAMs), a pivotal component of the tumor microenvironment (TME), play an important role in the development and progression of colorectal cancer (CRC). However, the function of macrophage-related genes (MRGs) in CRC remains poorly understood. This research examined the role of MRGs in CRC.
methodsMRGs were identified by integrating the gene set that exhibited differential expression between tumor and non-tumor tissues in CRC with the gene set associated with TAMs identified by CIBERSORT. To establish a prognostic signature specifically related to TAMs, a combination of univariate Cox regression and least absolute shrinkage operator analyses was utilized. By incorporating oncoPredict, Tumor Immune Dysfunction and Exclusion, mutation, cancer stem cell index, and metastasis data, we were able to predict various clinical features such as drug sensitivity, chemical sensitivity, and immunotherapeutic response. Furthermore, RNA extraction from CRC tissues enabled the validation of differential expression in prognostic MRGs using quantitative real-time polymerase chain reaction (qRT-PCR).
resultsHigh TAM infiltration was positively associated with poor prognosis, and the macrophage-related gene (MRG) risk score showed a strong correlation with patient survival. The high-risk group demonstrates better immunotherapy response and six of the eight prognostic genes identified were associated with metastasis, suggesting that the high-risk group may be more susceptible to metastasis. The expression levels of two protective genes, MRPS7 and ORC1, were higher in normal tissues compared to tumor tissues.
conclusionOur findings could provide insights into the role of TAMs in predicting CRC prognosis and suggest potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.